Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial.

Saved in:
Bibliographic Details
Title: Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial.
Authors: Wick W; Neurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de., Lanz LM; NCT Trial Center, University Clinic Heidelberg, Heidelberg University & German Cancer Research Center, Heidelberg, Germany., Wick A; Neurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany., Harting I; Neuroradiology, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany., Dettmer S; NCT Trial Center, University Clinic Heidelberg, Heidelberg University & German Cancer Research Center, Heidelberg, Germany., Suwala AK; Neuropathology, University Clinic Heidelberg, Heidelberg University & German Cancer Research Center, Heidelberg, Germany., Ketter R; Neurosurgery, Saarland University, Homburg, Germany., Tabatabai G; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University, Tübingen, Germany.; Centre for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, Tübingen, Germany., Seliger C; Neurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany.; Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany., Glas M; Division of Clinical Neurooncology, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany., Burger MC; Dr. Senckenberg Institute of Neurooncology, Goethe University Frankfurt and Goethe University Hospital, Frankfurt, Germany., Timmer M; Department of Neurosurgery, University Hospital Cologne, Cologne, Germany., Ringel FA; Neurosurgery, University Medicine Mainz, Mainz, Germany.; Neurosurgery Clinic, Ludwig Maximilians University (LMU), Munich, Germany., Mildenberger I; German Cancer Consortium (DKTK) & CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center Heidelberg, Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience (MCTN), Heidelberg University & DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany., Schulz-Schaeffer WJ; Neuropathology, Saarland University, Homburg, Germany., Winkler F; Neurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany., König L; Department of Radiation Oncology, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany., Herold-Mende C; Division of Experimental Neurosurgery, Neurosurgery Clinic, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany., Eisenmenger A; NCT Trial Center, University Clinic Heidelberg, Heidelberg University & German Cancer Research Center, Heidelberg, Germany., Pfister SM; Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Division of Pediatric Neurooncology, Heidelberg University Hospital, Department of Pediatric Hematology and Oncology, National Center for Tumor Dieseases (NCT), Heidelberg, Germany., Renovanz M; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University, Tübingen, Germany.; Centre for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, Tübingen, Germany.; Department of Neurosurgery, University Hospital Tübingen, Tübingen, Germany., Bendszus M; Neuroradiology, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany., Sahm F; Neuropathology, University Clinic Heidelberg, Heidelberg University & German Cancer Research Center, Heidelberg, Germany. felix.sahm@med.uni-heidelberg.de., Platten M; German Cancer Consortium (DKTK) & CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center Heidelberg, Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience (MCTN), Heidelberg University & DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany., Kessler T; Neurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany.
Source: Nature medicine [Nat Med] 2025 Oct; Vol. 31 (10), pp. 3534-3541. Date of Electronic Publication: 2025 Sep 05.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-025-03928-9